NeuPath Health (NPTH) Q3 2024 earnings summary

Executive summary

• Achieved total revenue of $17.6 million for Q3 2024, up 9% year-over-year, and $53.9 million for the nine months, also up 9% year-over-year.

• Adjusted EBITDA reached $0.7 million for Q3 and $2.9 million for the nine months, up 9% and 20% year-over-year, respectively.

• Marked the 23rd consecutive quarter of positive adjusted EBITDA, reflecting ongoing operational improvements.

• Positive cash flow and net debt reduced by 8% versus September 30, 2023.

Financial highlights

• Clinic revenue was $16.3 million for Q3 2024, up from $14.9 million in Q3 2023, driven by higher fluoroscopy revenues and increased patient volumes.

• Non-clinic revenue remained stable at $1.2 million for Q3 2024, with nine-month non-clinic revenue rising to $4.1 million from $3.6 million year-over-year.

• Gross margin for Q3 2024 was 18.3%, unchanged from Q3 2023; nine-month gross margin improved to 19.0% from 18.4% year-over-year.

• Net and comprehensive loss for Q3 2024 was $323,000, compared to income of $356,000 in Q3 2023.

Outlook and guidance

• Management expects continued operational improvements and is investing in clinic facilities to drive future growth.

• Evaluating new opportunities for both organic and inorganic growth to expand services and reach.